Kappa Bioscience AS

Kappa Bioscience offers high purity vitamin K2 as menaquinone-7 (MK-7). As the innovative leader and first mover of vitamin K2 MK-7, the company have extensive knowledge about vitamins and are currently the only vendor with vitamin K2 as pure MK-7 in various formulations. Based on the self-affirmed GRAS approval, Kappas K2 MK-7 can also be used in conventional foods.

Founded in December 2006, Kappa Bioscience is a Norwegian based entity that takes pride in following a traditional vitamin production process with propriety and innovative new steps. One of the core assets is the patent covering the production of pure vitamin K2 as menaquinone‑7.

On October 29, 2019, Kistefos announced a sale of the majority shareholding in Kappa Bioscience to a fund managed by the private equity company Verdane. Management reinvested parts of their consideration alongside Verdane.

Kistefos’ consideration for its ownership share was MNOK 396, which constitute a booked profit of approximately MNOK 340 and an multiple of cost of about 8x. During the five years of direct Kistefos ownership, Kappa Bioscience conducted two acquisitions and outperformed competitors in organic growth.